These experiments showed that the knockdown of GRPEL2, provoking anti-tumor growth, inhibiting tumor proliferation, and mediating non-mitochondrial cytosolic glycolysis, could further manipulate intracellular ROS-induced GBM proliferation, eventually leading to the abrogated metabolic activity of GBM tumor cells. The gene discussed is GRPEL2; the disease is glioblastoma.